10896 results for 'full t from'

Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance

Low-dose IL-2 expands regulatory T cells. High-dose IL-2 expands the cells they exist to restrain. Same cytokine, same receptor family, opposite clinical intent — and the explanation is a receptor su

The innate immune system, a primary line of defense against pathogens, comprises various cellular and molecular mechanisms. Among these, the Nod-like Receptor (NLR) signaling pathways play a criti

Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha

Two asthma biologics have opposite effects on the blood eosinophil count, and both of them work. Mepolizumab empties the eosinophil compartment; dupilumab can transiently raise it. If that seems cont

The intricate process of stem cell differentiation and self-renewal is a cornerstone of developmental biology and regenerative medicine. At the heart of this complex regulatory mechanism are trans

Inflammasomes are complex intracellular structures that play a pivotal role in the immune response by detecting pathogenic microorganisms and sterile stressors. Their activation is a critical step

Cell Cycle · KinasesCyclins and Cyclin-Dependent Kinases: Regulation, Substrates and Mitotic ControlCDKs are inactive on their own. They require a cyclin partner, and because cyclin levels rise and fa

Protocols & Assay Guides | ELISA, Multiplex, Western Blot | Assay Genie

What if our first line of immune defense, the innate immune system, could learn from past encounters to fight future battles more effectively? For decades, we believed this was the exclusive domain of

Quick Facts About NatalizumabWhat is Natalizumab?Natalizumab is a monoclonal antibody used to treat multiple sclerosis (MS) and Crohn's disease. It works by blocking immune cells from at

Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen

Not one immune cytokine on this pathway touches bone. TNF, IL-1β, IL-6 and IL-17A all act on osteoblasts, osteocytes and synovial fibroblasts, and it is those stromal cells that decide between RANKL

Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like

Almost any inflammatory phenotype in a mouse can be assigned to a cytokine by taking that cytokine away. Neutralisation is the most direct causal test immunology has: inject a functional-grade antibo